Microcap Ledger Alaunos Therapeutics, Inc. $TCRT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Fort Lauderdale, FL
- Fiscal year end
- December 31
- Shares outstanding
- 2,540,480 [10-Q 2026-08-14]
What the company doesAI summary of filing
Alaunos Therapeutics is a preclinical-stage biopharmaceutical company developing orally administered small-molecule therapeutics for obesity and metabolic disorders through a non-hormonal mechanism. The company's lead program, ALN1003, has generated preclinical proof-of-concept data in mouse studies showing dose-dependent body weight loss, liver weight reduction, and improved metabolic biomarkers. Alaunos is pre-revenue, has not generated product revenue, reported a net loss of $4.2 million for the year ended December 31, 2025, and expects to require significant additional capital to fund operations and advance its programs. The company was previously focused on clinical-stage TCR-T cell therapies for oncology but discontinued that program in August 2023. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$1.96M | −$1.33M | $124.0K | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $5.0K | −$4.18M | −$2.87M | $1.39M | [10-K 2026-03-31] |
| FY ended Dec 2024 | $10.0K | −$4.68M | −$4.97M | $1.09M | [10-K 2026-03-31] |
- Quarterly cash burn
- −$665.5K
- Cash runway Estimate
- ~0.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-04-30 | 1,639,521 | [10-K/A 2025-04-30] |
| 2025-05-15 | 1,639,521 | [10-Q 2025-05-15] |
| 2025-08-14 | 2,194,941 | [10-Q 2025-08-14] |
| 2025-11-14 | 2,231,829 | [10-Q 2025-11-14] |
| 2026-03-31 | 2,378,253 | [10-K 2026-03-31] |
| 2026-04-30 | 2,402,372 | [10-K/A 2026-04-30] |
| 2026-05-15 | 24,422,146 | [10-Q 2026-05-15] |
| 2026-08-14 | 2,540,480 | [10-Q 2026-08-14] |
- Shelf registration
- S-1 filed 2025-10-22; no effectiveness notice found in EDGAR [S-1 2025-10-22]
Listing status
Current status: 4 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-10-09. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-10-09 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-10-09] |
| 2026-04-15 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-04-15] |
| 2025-07-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-07-02] |
| 2025-04-11 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-11] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-06 | Weis Holger | grant | 23,564 | $0.74 | [4 2026-10-08] |
| 2026-10-06 | Vieser Jaime | grant | 22,669 | $0.74 | [4 2026-10-08] |
| 2026-10-06 | Postma Robert W | grant | 21,829 | $0.74 | [4 2026-10-08] |
| 2026-10-06 | Jerman Michael Allen | grant | 20,990 | $0.74 | [4 2026-10-08] |
| 2026-08-06 | Weis Holger | grant | 4,363 | $2.01 | [4 2026-08-11] |
| 2026-07-23 | Jerman Michael Allen | grant | 8,138 | $1.92 | [4 2026-07-27] |
| 2026-07-23 | Weis Holger | grant | 4,568 | $1.92 | [4 2026-07-27] |
| 2026-07-23 | Postma Robert W | grant | 8,463 | $1.92 | [4 2026-07-27] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 8-K | Listing notice or transfer |
| 2026-09-22 | 8-K | Material agreement entered; Other events |
| 2026-09-21 | 424B3 | Prospectus or prospectus supplement |
| 2026-09-17 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-06-29 | 8-K | Other events |
| 2026-05-26 | 8-K | Other events |
| 2026-05-18 | 8-K | Other events |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-04-30 | 10-K/A | Amended report |
| 2026-04-15 | 8-K | Listing notice or transfer |
| 2026-03-31 | 10-K | Annual report |
Alerts for $TCRT
Email me when Alaunos Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.